Factors determining long-term success of biologic therapy in rheumatoid arthritis
The necessity to achieve clinical remission or low disease activity in every patient with rheumatoid arthritis highlights the importance of combination therapy with methotrexate and biological agents for treatment of resistant to conventional disease-modifying anti-rheumatic drugs patients. Modern r...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2015-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/640 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839574159140585472 |
|---|---|
| author | Dmitry Evgenyevich Karateev |
| author_facet | Dmitry Evgenyevich Karateev |
| author_sort | Dmitry Evgenyevich Karateev |
| collection | DOAJ |
| description | The necessity to achieve clinical remission or low disease activity in every patient with rheumatoid arthritis highlights the importance of combination therapy with methotrexate and biological agents for treatment of resistant to conventional disease-modifying anti-rheumatic drugs patients. Modern requirements mean not only the achievement of results but also long-term maintaining of success. The possibility to get stable results of treatment is determined by many factors such as: clinical efficacy, safety, low immunogenicity, persistence on therapy and the economic feasibility. Analysis of published data for last 5 years leads to the conclusion that etanercept has an optimal combination of these parameters among inhibitors of tumor necrosis factor alpha. |
| format | Article |
| id | doaj-art-746d3ca747cf4befa2a92db0719005d3 |
| institution | Matheson Library |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2015-09-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-746d3ca747cf4befa2a92db0719005d32025-08-04T14:00:33ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2015-09-0193546010.14412/1996-7012-2015-3-54-601934Factors determining long-term success of biologic therapy in rheumatoid arthritisDmitry Evgenyevich Karateev0V.A. Nasonova Research Institute of RheumatologyThe necessity to achieve clinical remission or low disease activity in every patient with rheumatoid arthritis highlights the importance of combination therapy with methotrexate and biological agents for treatment of resistant to conventional disease-modifying anti-rheumatic drugs patients. Modern requirements mean not only the achievement of results but also long-term maintaining of success. The possibility to get stable results of treatment is determined by many factors such as: clinical efficacy, safety, low immunogenicity, persistence on therapy and the economic feasibility. Analysis of published data for last 5 years leads to the conclusion that etanercept has an optimal combination of these parameters among inhibitors of tumor necrosis factor alpha.https://mrj.ima-press.net/mrj/article/view/640tumor necrosis factor alpharheumatoid arthritisetanerceptsafetyimmunogenicitypersistence on therapy |
| spellingShingle | Dmitry Evgenyevich Karateev Factors determining long-term success of biologic therapy in rheumatoid arthritis Современная ревматология tumor necrosis factor alpha rheumatoid arthritis etanercept safety immunogenicity persistence on therapy |
| title | Factors determining long-term success of biologic therapy in rheumatoid arthritis |
| title_full | Factors determining long-term success of biologic therapy in rheumatoid arthritis |
| title_fullStr | Factors determining long-term success of biologic therapy in rheumatoid arthritis |
| title_full_unstemmed | Factors determining long-term success of biologic therapy in rheumatoid arthritis |
| title_short | Factors determining long-term success of biologic therapy in rheumatoid arthritis |
| title_sort | factors determining long term success of biologic therapy in rheumatoid arthritis |
| topic | tumor necrosis factor alpha rheumatoid arthritis etanercept safety immunogenicity persistence on therapy |
| url | https://mrj.ima-press.net/mrj/article/view/640 |
| work_keys_str_mv | AT dmitryevgenyevichkarateev factorsdetermininglongtermsuccessofbiologictherapyinrheumatoidarthritis |